AG
ALDX icon

Algert Global’s Aldeyra Therapeutics ALDX Stock Holding History

Algert Global’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,670
Closed -$51K – 1486
2024
Q1 		$51K Buy
+15,670
New +$51.5K ﹤0.01% 1033
2023
Q3 		– Sell
-72,310
Closed -$607K – 1091
2023
Q2 		$607K Buy
+72,310
New +$712K 0.03% 774
2021
Q1 		– Sell
-27,100
Closed -$186K – 431
2020
Q4 		$186K Hold
27,100
– – 0.05% 352
2020
Q3 		$201K Buy
27,100
+3,570
+15% +$23.1K 0.06% 314
2020
Q2 		$98K Sell
23,530
-6,920
-23% -$25.3K 0.03% 377
2020
Q1 		$75K Buy
+30,450
New +$137K 0.03% 367
2019
Q3 		– Sell
-29,840
Closed -$179K – 362
2019
Q2 		$179K Buy
29,840
+6,631
+29% +$49.9K 0.07% 288
2019
Q1 		$210K Sell
23,209
-9,725
-30% -$82.6K 0.12% 242
2018
Q4 		$273K Buy
+32,934
New +$337K 0.08% 298
2018
Q3 		– Sell
-10,424
Closed -$83K – 343
2018
Q2 		$83K Buy
+10,424
New +$83.2K 0.02% 324

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Algert Global's ALDX Position: Q2 2024 in Review

Algert Global sold out of Aldeyra Therapeutics (ALDX) in Q2 2024, closing a stake of 15,670 shares — an estimated $51K sold.

Algert Global first reported a position in ALDX in Q2 2018 and held it in 10 quarters. The position peaked at $607K in Q2 2023. 103 funds tracked by Wall St. Rank hold ALDX as of Q2 2024.

  • Algert Global reported no remaining Aldeyra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Algert Global sold 15,670 Aldeyra Therapeutics shares in Q2 2024, an estimated $51K.
  • Algert Global first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 10 quarters.
  • Algert Global's Aldeyra Therapeutics position peaked at $607K in Q2 2023.
  • 103 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2024.

Based on Algert Global's 13F filing for Q2 2024, filed 15 Aug 2024.